NASDAQ:KMPH - KemPharm Stock Price, Price Target & More

$5.15 -0.20 (-3.74 %)
(As of 04/25/2018 01:54 PM ET)
Previous Close$5.35
Today's Range$5.00 - $5.53
52-Week Range$2.45 - $8.40
Volume94,223 shs
Average Volume160,303 shs
Market Capitalization$86.10 million
P/E Ratio-1.81
Dividend YieldN/A
Beta-0.34

About KemPharm (NASDAQ:KMPH)

KemPharm logoKemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa.

Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMPH
CUSIPN/A
Phone319-665-2575

Debt

Debt-to-Equity Ratio-1.56%
Current Ratio4.09%
Quick Ratio4.09%

Price-To-Earnings

Trailing P/E Ratio-1.81
Forward P/E Ratio-1.99
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($3.92) per share
Price / Book-1.31

Profitability

EPS (Most Recent Fiscal Year)($2.96)
Net Income$-43,380,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-61.29%

Miscellaneous

Employees32
Outstanding Shares15,100,000

How to Become a New Pot Stock Millionaire

KemPharm (NASDAQ:KMPH) Frequently Asked Questions

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How were KemPharm's earnings last quarter?

KemPharm (NASDAQ:KMPH) posted its earnings results on Thursday, March, 29th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.04. View KemPharm's Earnings History.

What price target have analysts set for KMPH?

4 Wall Street analysts have issued 1-year price targets for KemPharm's shares. Their predictions range from $9.00 to $13.00. On average, they expect KemPharm's share price to reach $10.75 in the next twelve months. View Analyst Ratings for KemPharm.

Are investors shorting KemPharm?

KemPharm saw a drop in short interest in the month of March. As of March 15th, there was short interest totalling 349,858 shares, a drop of 39.5% from the February 28th total of 577,914 shares. Based on an average trading volume of 147,317 shares, the short-interest ratio is currently 2.4 days. Currently, 3.0% of the company's shares are short sold.

Who are some of KemPharm's key competitors?

Who are KemPharm's key executives?

KemPharm's management team includes the folowing people:
  • Dr. Travis C. Mickle Ph.D., Co-Founder, Pres, Chief Exec. Officer & Chairman (Age 45)
  • Mr. Daniel L. Cohen, Exec. VP of Gov. & PR (Age 59)
  • Dr. Sven Guenther Ph.D., Exec. VP of R&D (Age 46)
  • Mrs. Christal M. M. Mickle M.A., Co-Founder & VP of Operations & Product Devel. (Age 39)
  • Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 46)

When did KemPharm IPO?

(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Has KemPharm been receiving favorable news coverage?

Media headlines about KMPH stock have been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. KemPharm earned a coverage optimism score of 0.08 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 45.65 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $5.15.

How big of a company is KemPharm?

KemPharm has a market capitalization of $86.10 million. The specialty pharmaceutical company earns $-43,380,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. KemPharm employs 32 workers across the globe.

How can I contact KemPharm?

KemPharm's mailing address is 2500 CROSSPARK ROAD SUITE E126, CORALVILLE IA, 52241. The specialty pharmaceutical company can be reached via phone at 319-665-2575 or via email at [email protected]


MarketBeat Community Rating for KemPharm (KMPH)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe KMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

KemPharm (NASDAQ:KMPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for KemPharm in the last 12 months. Their average twelve-month price target is $10.75, suggesting that the stock has a possible upside of 108.74%. The high price target for KMPH is $13.00 and the low price target for KMPH is $9.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.75$10.25$9.25$9.00
Price Target Upside: 108.74% upside32.77% upside86.87% upside181.25% upside

KemPharm (NASDAQ:KMPH) Consensus Price Target History

Price Target History for KemPharm (NASDAQ:KMPH)

KemPharm (NASDAQ:KMPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2018Roth CapitalSet Price TargetBuy$10.00MediumView Rating Details
4/2/2018OppenheimerSet Price TargetBuy$13.00MediumView Rating Details
2/23/2018Canaccord GenuitySet Price TargetBuy -> Buy$7.00 -> $11.00LowView Rating Details
1/16/2018Royal Bank of CanadaSet Price TargetBuy$9.00MediumView Rating Details
(Data available from 4/25/2016 forward)

Earnings

KemPharm (NASDAQ:KMPH) Earnings History and Estimates Chart

Earnings by Quarter for KemPharm (NASDAQ:KMPH)

KemPharm (NASDAQ:KMPH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.72)($0.72)($0.72)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.57)($0.57)($0.57)

KemPharm (NASDAQ KMPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018Q4 2017($0.68)($0.72)ViewListenView Earnings Details
11/9/2017Q3 2017($0.69)($0.68)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.63)($0.44)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.63)($0.84)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.70)($0.68)ViewListenView Earnings Details
11/9/2016Q3 2016($0.70)($0.92)ViewListenView Earnings Details
8/10/2016Q2($0.94)($0.58)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.20)ViewListenView Earnings Details
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details
11/12/2015Q315($0.48)($0.68)ViewListenView Earnings Details
8/13/2015Q215($0.47)($0.59)ViewListenView Earnings Details
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

KemPharm (NASDAQ:KMPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

KemPharm (NASDAQ KMPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.40%
Institutional Ownership Percentage: 35.50%
Insider Trading History for KemPharm (NASDAQ:KMPH)
Insider Trading History for KemPharm (NASDAQ:KMPH)

KemPharm (NASDAQ KMPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/27/2017Daniel L CohenEVPBuy7,500$3.79$28,425.00View SEC Filing  
9/25/2017R. Laduane CliftonCFOBuy300$3.78$1,134.001,575View SEC Filing  
9/14/2017Delaware Street Capital MasterMajor ShareholderBuy325,888$3.27$1,065,653.76View SEC Filing  
8/24/2017Daniel L CohenEVPBuy5,000$2.58$12,900.0025,000View SEC Filing  
8/24/2017Gordon K JohnsonInsiderBuy4,000$2.60$10,400.003,000View SEC Filing  
6/20/2017Travis C MickleCEOBuy8,000$3.45$27,600.001,629,612View SEC Filing  
6/19/2017R. Laduane CliftonCFOBuy275$3.30$907.501,275View SEC Filing  
5/25/2017Daniel L CohenEVPBuy2,500$4.11$10,275.0019,474View SEC Filing  
3/31/2017Daniel L CohenEVPBuy2,500$4.48$11,200.0016,500View SEC Filing  
3/24/2017R. Laduane CliftonCFOBuy1,000$4.24$4,240.00900View SEC Filing  
3/22/2017Travis C MickleCEOBuy2,000$4.10$8,200.001,526,081View SEC Filing  
3/20/2017David S TierneyDirectorBuy1,000$4.20$4,200.006,000View SEC Filing  
11/30/2016Daniel L CohenEVPBuy5,000$3.50$17,500.0010,747View SEC Filing  
9/6/2016Daniel L CohenEVPBuy10,000$4.75$47,500.001,310View SEC Filing  
8/17/2016Travis C MickleCEOBuy5,000$4.95$24,750.001,381,176View SEC Filing  
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.501,381,176View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

KemPharm (NASDAQ KMPH) News Headlines

Source:
DateHeadline
Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B VaccineBlog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
finance.yahoo.com - April 23 at 8:15 AM
KemPharm (KMPH) Lifted to Hold at Zacks Investment ResearchKemPharm (KMPH) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:16 PM
KemPharm (KMPH) Stock Rating Lowered by ValuEngineKemPharm (KMPH) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 18 at 1:24 PM
 Analysts Anticipate KemPharm (KMPH) Will Post Earnings of -$0.70 Per Share Analysts Anticipate KemPharm (KMPH) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 9 at 5:24 PM
KemPharm (KMPH) Upgraded to Sell by ValuEngineKemPharm (KMPH) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 6 at 11:39 AM
KemPharm (KMPH) Upgraded at ValuEngineKemPharm (KMPH) Upgraded at ValuEngine
www.americanbankingnews.com - April 6 at 11:38 AM
KemPharm (KMPH) Downgraded by Zacks Investment ResearchKemPharm (KMPH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 6 at 10:03 AM
KemPharm (KMPH) Raised to Buy at Zacks Investment ResearchKemPharm (KMPH) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 5 at 1:43 PM
Kempharm Removes The Albatross From Its Neck: Where Is The Company Now Sailing? (Update On Apadaz)Kempharm Removes The Albatross From Its Neck: Where Is The Company Now Sailing? (Update On Apadaz)
seekingalpha.com - April 5 at 10:11 AM
Oppenheimer Analysts Reduce Earnings Estimates for KemPharm (KMPH)Oppenheimer Analysts Reduce Earnings Estimates for KemPharm (KMPH)
www.americanbankingnews.com - April 5 at 7:38 AM
KemPharm (KMPH) Given Consensus Rating of "Buy" by BrokeragesKemPharm (KMPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 1:39 AM
KemPharm (KMPH) Given a $10.00 Price Target at Roth CapitalKemPharm (KMPH) Given a $10.00 Price Target at Roth Capital
www.americanbankingnews.com - April 3 at 11:11 AM
Oppenheimer Analysts Give KemPharm (KMPH) a $13.00 Price TargetOppenheimer Analysts Give KemPharm (KMPH) a $13.00 Price Target
www.americanbankingnews.com - April 2 at 12:26 PM
Kempharm (KMPH): Attention Shifting to KP415 Mid-Year Update - RBCKempharm (KMPH): Attention Shifting to KP415 Mid-Year Update - RBC
www.streetinsider.com - April 2 at 8:40 AM
KemPharm Inc (KMPH) Short Interest UpdateKemPharm Inc (KMPH) Short Interest Update
www.americanbankingnews.com - March 31 at 1:45 AM
KemPharm (KMPH) Rating Increased to Buy at Zacks Investment ResearchKemPharm (KMPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 8:24 PM
KemPharm (KMPH) Issues  Earnings ResultsKemPharm (KMPH) Issues Earnings Results
www.americanbankingnews.com - March 30 at 8:30 AM
KemPharms (KMPH) CEO Travis Mickle on Q4 2017 Results - Earnings Call TranscriptKemPharm's (KMPH) CEO Travis Mickle on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 30 at 8:23 AM
Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH)Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH)
finance.yahoo.com - March 30 at 8:23 AM
KemPharm (KMPH) Rating Lowered to Hold at Zacks Investment ResearchKemPharm (KMPH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 7:28 PM
KemPharm (KMPH) Stock Rating Upgraded by Zacks Investment ResearchKemPharm (KMPH) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:43 AM
KemPharm (KMPH) Shares March Higher, Can It Continue? March 23, 2018KemPharm (KMPH) Shares March Higher, Can It Continue? March 23, 2018
www.zacks.com - March 25 at 8:27 AM
KemPharm (KMPH) Stock Rating Lowered by Zacks Investment ResearchKemPharm (KMPH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:46 PM
 Brokerages Expect KemPharm Inc (KMPH) Will Announce Earnings of -$0.71 Per Share Brokerages Expect KemPharm Inc (KMPH) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - March 23 at 5:16 PM
KemPharm (KMPH) Stock Rating Reaffirmed by OppenheimerKemPharm (KMPH) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - March 22 at 4:09 PM
KemPharm (KMPH) Reports Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHDKemPharm (KMPH) Reports Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD
www.streetinsider.com - March 21 at 5:37 PM
FDA Nod For SGENs Adcetris, Antibe Soars On GI Data, CHMA Empowered - NasdaqFDA Nod For SGEN's Adcetris, Antibe Soars On GI Data, CHMA Empowered - Nasdaq
www.nasdaq.com - March 21 at 8:49 AM
KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results - GlobeNewswire (press release)KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results - GlobeNewswire (press release)
globenewswire.com - March 21 at 8:49 AM
KemPharm, Inc. to Report Fourth Quarter and Year End 2017 ResultsKemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results
finance.yahoo.com - March 21 at 8:49 AM
BRIEF-Kempharm Announces Positive Topline Results From KP415 Pharmacokinetic Study In Children And Adolescents With ADHDBRIEF-Kempharm Announces Positive Topline Results From KP415 Pharmacokinetic Study In Children And Adolescents With ADHD
www.reuters.com - March 20 at 5:17 PM
KemPharm (KMPH) Reports Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents ... - StreetInsider.comKemPharm (KMPH) Reports Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents ... - StreetInsider.com
www.streetinsider.com - March 20 at 8:28 AM
KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHDKemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD
finance.yahoo.com - March 20 at 8:28 AM
KemPharm (KMPH) Rating Increased to Sell at ValuEngineKemPharm (KMPH) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 10 at 7:42 PM
KemPharm Inc (KMPH) Receives Average Recommendation of "Buy" from BrokeragesKemPharm Inc (KMPH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 10 at 1:28 AM
KemPharm to Present at Upcoming Investor Conferences - GlobeNewswire (press release)KemPharm to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:15 AM
KemPharm to Present at Upcoming Investor ConferencesKemPharm to Present at Upcoming Investor Conferences
finance.yahoo.com - March 6 at 8:15 AM
At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy?At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy?
finance.yahoo.com - March 5 at 5:50 PM
KemPharm (KMPH) Cut to Strong Sell at ValuEngineKemPharm (KMPH) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - March 4 at 3:54 PM
Q1 2018 Earnings Forecast for KemPharm Inc (KMPH) Issued By OppenheimerQ1 2018 Earnings Forecast for KemPharm Inc (KMPH) Issued By Oppenheimer
www.americanbankingnews.com - February 28 at 8:08 AM
KemPharm (KMPH) Set to Announce Earnings on WednesdayKemPharm (KMPH) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:40 AM
Oppenheimer Weighs in on KemPharm Incs FY2022 Earnings (KMPH)Oppenheimer Weighs in on KemPharm Inc's FY2022 Earnings (KMPH)
www.americanbankingnews.com - February 27 at 4:36 PM
KemPharm (KMPH) Given a $13.00 Price Target at OppenheimerKemPharm (KMPH) Given a $13.00 Price Target at Oppenheimer
www.americanbankingnews.com - February 26 at 11:26 AM
KMPH Gets FDA Nod, ADMP On Track, OBSV To Report Data Today ... - NasdaqKMPH Gets FDA Nod, ADMP On Track, OBSV To Report Data Today ... - Nasdaq
www.nasdaq.com - February 26 at 8:17 AM
KemPharm Spikes On FDA Approval Of ApadazKemPharm Spikes On FDA Approval Of Apadaz
www.benzinga.com - February 25 at 8:30 AM
KemPharm (KMPH) Cut to Sell at ValuEngineKemPharm (KMPH) Cut to Sell at ValuEngine
www.americanbankingnews.com - February 25 at 12:36 AM
Canaccord Genuity Analysts Give KemPharm (KMPH) a $11.00 Price TargetCanaccord Genuity Analysts Give KemPharm (KMPH) a $11.00 Price Target
www.americanbankingnews.com - February 24 at 4:18 PM
KemPharm (KMPH) Reports FDA Approval of Apadaz for Short-Term Management of Acute PainKemPharm (KMPH) Reports FDA Approval of Apadaz for Short-Term Management of Acute Pain
www.streetinsider.com - February 23 at 5:58 PM
KemPharms opioid painkiller gets FDA approval, shares soarKemPharm's opioid painkiller gets FDA approval, shares soar
finance.yahoo.com - February 23 at 5:58 PM
Why KemPharm Inc’s (NASDAQ:KMPH) CEO Salary Matters To YouWhy KemPharm Inc’s (NASDAQ:KMPH) CEO Salary Matters To You
finance.yahoo.com - February 19 at 5:09 PM
 Analysts Anticipate KemPharm Inc (KMPH) Will Post Earnings of -$0.70 Per Share Analysts Anticipate KemPharm Inc (KMPH) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - February 17 at 7:14 PM

SEC Filings

KemPharm (NASDAQ:KMPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

KemPharm (NASDAQ:KMPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

KemPharm (NASDAQ KMPH) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.